Sumithira Vasu
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sumithira Vasu sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Sumithira Vasu: 6 sponsored US clinical trials, 2 recruiting.
Sumithira Vasu sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), with 2 trials.
Upper-quartile sponsor footprint
Sumithira Vasu sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
NCT05418088
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
NCT03665675
Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
NCT04220684
Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant
NCT03537599
Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
NCT02122081
Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02316964
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
Therapeutic Areas
What is open in the Sumithira Vasu pipeline
2 recruiting of 6 indexed (33% open); 3 completed (50%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sumithira Vasu: open-pipeline peers nationwide
Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Sumithira Vasu sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Sumithira Vasu page
6 registered trials is a research-attention snapshot, not an endorsement of Sumithira Vasu or any single study.
- 2 of Sumithira Vasu's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) is the condition Sumithira Vasu studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sumithira Vasu pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.